NASDAQ
27.03.26 | 20:59
10,600 US-Dollar
-1,67 % -0,180
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Phathom upgraded at Barclays following pullback, Voquezna optimism | 2 | Seeking Alpha | ||
| Fr | Barclays stuft Phathom Pharmaceuticals wegen positiver Umsatzprognose hoch | 3 | Investing.com Deutsch | ||
| Fr | Barclays upgrades Phathom Pharmaceuticals stock rating on revenue outlook | 4 | Investing.com | ||
| PHATHOM PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 27.02. | Guggenheim raises Phathom stock price target to $25 on revenue beat | 1 | Investing.com | ||
| 26.02. | Phathom outlines $320M-$345M 2026 revenue guidance as company targets operating profitability | 1 | Seeking Alpha | ||
| 26.02. | Stifel reiterates Buy on Phathom stock, keeps $28 price target | 3 | Investing.com | ||
| 26.02. | Phathom Q4 2025 slides: 217% revenue growth, profitability in sight | 3 | Investing.com | ||
| 26.02. | Phathom Pharmaceuticals, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.02. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.01. | Phathom Pharmaceuticals: Stifel bekräftigt "Buy"-Rating nach starkem Umsatzausblick | 7 | Investing.com Deutsch | ||
| 15.01. | Phathom Pharmaceuticals stock maintains Buy rating at Stifel on strong revenue outlook | 4 | Investing.com | ||
| 14.01. | Cantor Fitzgerald reiterates Overweight rating on Phathom stock at $29 | 2 | Investing.com | ||
| 14.01. | Cantor Fitzgerald bestätigt "Overweight" für Phathom und sieht 86 % Kurspotenzial | 6 | Investing.com Deutsch | ||
| 08.01. | Phathom Pharma Shows Sales Strength, Targets 2026 Profitability | 5 | Benzinga.com | ||
| 08.01. | Phathom Pharmaceuticals prices $130 million public offering | 12 | Investing.com | ||
| 08.01. | Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) | ||
| 07.01. | Phathom Pharmaceuticals announces public offering of common stock | 3 | Investing.com | ||
| 07.01. | Phathom Pharma plans public offering after reporting preliminary 2025 results | 1 | Seeking Alpha | ||
| 07.01. | Phathom Pharmaceuticals kündigt nach Kursrallye öffentliches Aktienangebot an | 5 | Investing.com Deutsch | ||
| 07.01. | Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIKING THERAPEUTICS | 28,210 | -4,98 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,584 | +3,20 % | BioCryst strebt Milliardenumsatz an und stärkt HAE-Portfolio mit Navenibart | ||
| IMMUNITYBIO | 6,648 | +3,13 % | ImmunityBio-Aktie -21%: Buy the dip? | Es ist eine nervenaufreibende Woche für ImmunityBio-Aktionäre. Nachdem der Kurs des Biotech-Unternehmens am Montag +10% in die Höhe schoss, ging es am gestrigen Dienstag um atemberaubende -21% nach... ► Artikel lesen | |
| MICROBOT MEDICAL | 2,268 | +0,35 % | Microbot Medical Inc. - 10-K, Annual Report | ||
| ATAIBECKLEY | 3,220 | +4,55 % | Psychedelika-Forschung gewinnt an Dynamik: Emyria Limited und AtaiBeckley im Fokus neuer PTBS-Therapien | ||
| CYTOKINETICS | 55,50 | +0,91 % | Cytokinetics, Incorporated: Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update | MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,448 | -3,96 % | Voyager Therapeutics, Inc.: Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results | - Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies... ► Artikel lesen | |
| CAPRICOR | 26,550 | +2,91 % | Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 6,760 | -4,38 % | Cathie Wood's ARK sells Nvidia stock, buys Arcturus Therapeutics | ||
| ZEVRA THERAPEUTICS | 8,150 | 0,00 % | Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million | BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare... ► Artikel lesen | |
| ABEONA THERAPEUTICS | 3,840 | +1,59 % | Abeona Therapeutics Inc.: Abeona Therapeutics Reports Full Year 2025 Financial Results and Corporate Updates | - First ZEVASKYN- commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 - - $191.4M in cash, cash equivalents and short-term investments as... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 16,900 | +3,05 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update | $49.1 million global net product revenue of EKTERLY (sebetralstat) for the eight months ended December 31, 2025 1,702 patient start forms received in the US from launch through end of February... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,415 | -6,03 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 101,00 | -0,98 % | Palvella Therapeutics Inc.: Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting | Poster #76954 highlights QTORIN rapamycin's single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven skin diseases while overcoming the crystallization... ► Artikel lesen | |
| ALIGOS THERAPEUTICS | 6,000 | -2,44 % | Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results | SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biotechnology company focused on improving patient outcomes through... ► Artikel lesen |
Das Unternehmen PHATHOM PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 10,600 Euro und damit -1,67 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHATHOM PHARMACEUTICALS INC finden Sie auf Wallstreet Online.